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SUMMARY
A community-based seroepidemiological survey of Addis Ababa, Ethiopia was conducted in 1994
to inform on the transmission dynamics and control of hepatitis B virus (HBV) infection. Venous
blood from 4736 individuals under 50 years of age from 1262 households, selected using stratiﬁed
cluster-sampling, was screened for HBV markers using commercial ELISAs. HBsAg prevalence
was 7% (95% CI 6–8), higher in males (9%; 7–10) than females (5%; 4–6). HBeAg prevalence
in HBsAg positives was 23% (18–29), and less than 1% of women of childbearing age were
HBeAg positive. Overall HBV seroprevalence (any marker), rose steadily with age to over 70% in
40–49 year olds, indicating signiﬁcant childhood and adult transmission. Estimated instantaneous
incidence was 3–4/100 susceptibles/year, higher in males than females in 0–4 year olds, and
peaking in early childhood and young adults. The age at which 50% had evidence of infection
was around 20 years, and the herd immunity threshold is approximated at 63–77%. Addis Ababa
is of intermediate-high HBV endemicity, with negligible perinatal transmission. Our main ﬁndings
are the identiﬁcation of a signiﬁcant diﬀerence between males and females in the age-acquisition
of HBV infection, and marked diﬀerences between age groups in HBV incidence rates. These
results should target future research studies of underlying risk factors. Furthermore, we generate
a crude estimate of the level of coverage of HBV vaccine that would be required to eliminate
the virus from the study population.
INTRODUCTION
Cross-sectional community studies of serological
markers of HBV infection have an important role
in identifying population endemicity, possible routes
of transmission and associated risk factors [1–9].
Such data help in the development of appropriate
control measures, for example, estimating the opti-
mal age for vaccine delivery, the level of vaccine
coverage required for elimination, and possible
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high-risk target groups [10, 11]. They support pre-
dictive mathematical models by which to explore
the merits of diﬀerent control options [11–13], to
assess cost-eﬀectiveness of intervention programmes
[14], and to predict the risk of evolution of escape
mutants [15].
Expansion of the HBV survey database is most
pressing in the developing world, where the burden
of HBV associated liver disease, and the need for
vaccine intervention, is highest [16]. In Africa, in
particular, uncertainty remains in the relative im-
portance of diﬀerent routes of HBV transmission and
in the underlying risk factors for infection especially
for childhood horizontal transmission [16]. Whilst
there are numerous serological surveys reported in
the literature, few have been designed to obtain data
representative of the socio-behavioural and demo-
graphic structure of the community. Greater attention
needs to focus upon adequate sample size and sam-
pling design to obtain precise and unbiased incidence
and prevalence estimates. Such data can be used to
provide realistic estimates of the level of coverage
needed to control infection. Additionally, ﬁnely age-
stratiﬁed data support investigation of heterogeneity,
by age and gender in incidence rates ; providing in-
sight into possible risk factors for, and routes of,
transmission and the potential impact of community
vaccination [10].
There is a body of literature on hepatitis B in
Ethiopia relating its public health importance [17–19],
and giving information on the pattern of HBV mar-
kers in various geographical locations, age and social
groups, and risk categories [9, 20–28]. Our study
builds upon this earlier work, providing signiﬁcantly
more detailed and representative data onHBVmarker
seroprevalence for the capital city of Addis Ababa.
Through this it has been possible to characterize the
transmission patterns of HBV and deﬁne vaccine
coverage required for control for an urban developing
country population.
METHODS
Emphasis is given to details not presented in pre-
vious related publications [29, 30]. Ethical approval
was obtained from authorities in Ethiopia (Ethical
Committee of the Ethiopian Health and Nutrition
Research Institute) and the United Kingdom (St
Mary’s Research Ethics Committee, London Univer-
sity).
Survey design and implementation
Addis Ababa, the capital city of Ethiopia situated on
the main plateau (altitude approx. 2000 m), has a
population of 2.1 m and a growth rate of 4%/annum
(1994 census). Demographic change in recent decades
has arisen from decreasing fertility (the crude birth
rate, CBR, has fallen from 35.5/yr in 1967 to 15.5/yr
in 1994), and high migration [31, 32]. Adminis-
tratively, the city is organised into 6 zones, compris-
ing 28 Waredas, sub-divided into 305 urban dwellers
associations or Kebeles (large housing estates) of
roughly 500–3000 households (see Fig. 1). All house-
holds are required to register with the Kebele oﬃce.
A multi-stage cluster sample design [33] was adopted,
with two strata formed by the inner (higher density,
y38 000/km2) and outer (lower density, y10000/
km2) city (note however that the average number of
occupants per household does not diﬀer between
strata). The Kebele formed the ﬁrst stage sampling
unit, and the household the second stage. For age
categories of single years up to age 4, and 5 yearly
from 5–49 years, and assuming a design eﬀect of 2
(in the absence of prior information) [33], a sample
size of 150 per age group would generate precision of
7–12% across the expected range of seroprevalence.
An estimated 1200 households were needed to reach
this sample size. We selected 20 Kebeles in each
stratum using probability proportional to estimated
size following standard procedures (Fig. 1) [34]. With-
in each of theKebeles 35 households (to allow for 15%
non-participation) were selected by simple random
sampling using the registers held at the Kebele oﬃce.
In the city periphery some registers required updating
due to recent house construction. Blood samples were
requested from all children under age 5 years, and
adults 15–49 years, and 1 in 2 children of school age
(5–14 years), as this age group had the highest rep-
resentation in the population.
Survey teams carried out household visits over the
period May to October of 1994. A household rep-
resented all individuals of a single family using the
same kitchen and sleeping in the same house, inclusive
of helper and visitors at time of survey. One house-
hold was selected at random from houses with mul-
tiple families. Informed consent was obtained from
the head of the household. Household heads were
interviewed using a pre-tested questionnaire on in-
dicators of socio-economic status, including years
of education of household head, house construction
and ownership, number of rooms and beds, utilities
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(water and light) and possession of radio. For each
individual in the household, information was re-
quested for age, sex, ethnicity, relationship to house-
hold head, years of residence in Addis Ababa, and
number of individuals who sleep in the same room.
Where possible, 5 ml of venous blood were obtained
from family members using sterile disposable needles
(21-23G) and Vacutainers (Becton Dickinson, Ban-
bury, England). Samples were transported in cool
boxes with ice blocks to the virology laboratory at the
EHNRI at the end of each day. Where needed, at least
two revisits were made to households to complete
interviews and blood sampling.
Laboratory screening methods
Serum collected from centrifuged clotted bloods
was stored in screw cap vials marked with a unique
KILLIL 14    ADMINISTRATIVE MAP
Fig. 1. The administrative structure of Addis Ababa showing the distribution of Kebeles sampled from the inner (black,
n=20) and outer (dark shading, n=20) strata of urban Addis Ababa. Note that Farmer’s Associations (denoted by light
shading and named) comprising rural Addis Ababa were excluded from the sampling frame.
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identiﬁer in three aliquots at x20 xC. Primary and
conﬁrmatory screening for antibodies to HBV core
antigen (anti-HBc) and for HBV surface antigen
(HBsAg) of all samples, and quantitative screening
for antibodies to hepatitis B surface antigen (anti-
HBs) of HBsAg negative samples, were carried out
using the Hepanostika range of kits (Hepanostika
AHBCUni-Form; HBsAgUni-Form II; AHBS New,
Organon Teknika, Boxtel, Belgium). HBsAg positive
samples were screened for HBeAg (Wellcozyme
HBeAg/anti-HBe, Murex, Dartford, England). All
kits were used according to the manufacturer’s in-
structions, excepting the anti-HBs assay where sam-
ples with an excess of 100 IU/L were not repeat
screened at higher dilution.
Data management and statistical analysis
In all data analyses account is taken of the stratiﬁed
cluster-based study design [33]. Probability weights
are applied to each outcome observation, with in-
creased weight given to data from the outer city due to
its greater size (inner :outer; 881781:1202807) and to
data from household clusters (Kebeles) with less than
average number of observations (since equal numbers
of households were expected from each cluster). Thus
observations from cluster i (i=1; n=40) in stratum
j ( j=1, 2; 1=inner, 2=outer) are given the following
weighting,Wij
Wij=
Pn
i=1ci
nci
 2sjP2
j=1sj
,
where the number of households selected in the ith
cluster is ci, and the census population size in the jth
stratum is sj. Furthermore, variance estimation for
statistical testing took into account the degree of
inter- versus intra-cluster variability for the ﬁrst stage
of cluster sampling, i.e. the Kebele. The analysis thus
makes some account for possible lack of indepen-
dence of observations within clusters of households,
though not explicitly between observations within
households. Estimates for total and adult population
prevalence of HBV markers (15–49 years) are pres-
ented standardized for diﬀerences in the age distri-
bution of the survey population (those providing a
blood sample) and the 1994 census. The weighting for
an observation in cluster i, stratum j, age class k
(k=0–4, …, 45–49) and gender l is Wijkl=Wij,Wkl,
with Wkl=ykl/zkl being the weighting applied to a
serological observation in inverse proportion to the
representation of its age class and gender in the survey
zkl=Zkl/Nb relative to the census ykl=Ykl/Nc. Here
Zkl and Nb are the numbers of blood samples in the
survey that are of age class k and gender l, and
in total, respectively, and Ykl and Nc the number of
individuals in the censused population that are in age
class k and gender l, and in total, respectively. All
statistical procedures were implemented in STATA
V6 (Stata Corporation, College Station, Texas, USA)
using the ‘svy’ commands, e.g. ‘svytab’ and ‘svylogit ’.
STATA svytab command produces asymmetric 95%
conﬁdence intervals (CI) for prevalence estimates
using a logit transform to ensure they lie between
1 and 0. We use the svylogit command to estimate
Odds Ratios (OR), with 95% CI, for comparisons
between prevalence in diﬀerent groups (e.g. males and
females).
Estimation of the rate of HBV transmission
Age-dependence in the force of infection (instan-
taneous per susceptible incidence) for hepatitis B in
the Addis Ababa population was investigated using
a piece-wise constant (PWC) catalytic infection model
[30]. The analysis ignored hepatitis-B related deaths,
and assumed that all infected individuals develop a
detectable serological response and retain at least one
serological marker up to at least age 49 years (the
upper age in the survey). We also assumed that HBV
transmission has not changed signiﬁcantly over the
last 50 years in the population. Under these assump-
tions, the change with age in the proportion sero-
logically positive reﬂects the age acquisition of HBV
infection of a birth cohort, and any variation in this
acquisition rate reﬂects age related phenomena and
not time-related changes in HBV transmission. It
follows that the proportion remaining susceptible
(i.e. serologically negative, having no marker of HBV
infection) at age a, x(a), is a function of the cumulat-
ive exposure to HBV infection from birth over a years
(i.e. the cumulative force of infection or cumulative
hazard). We modelled this cumulative incidence using
a PWC catalytic infection model, in which the force
of infection, li, is assumed constant in age class i, but
can vary between age classes (i.e. i=1, m), hence the
predicted proportion susceptible, xk(a) is deﬁned as
xk(a)=xk(aix1) exp [xli(axaix1)], (1)
where a(ix1)fafai and lio0. This modelled an ex-
ponential decay in the proportion susceptible between
age aix1 and age a due to an age-class speciﬁc force
of infection, li. We assumed there is no inﬂuence of
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maternal speciﬁc antibody and that perinatal trans-
mission was negligible [28], i.e. that all individuals
are born susceptible. The predicted proportion sero-
logically positive at age a is simply pk=1xxk(a). We
applied the model to yearly age group serological data
recording the number of individuals without any
HBV markers, S(a), out of a total tested, N(a) (each
adjusted by probability weights to account for the
stratiﬁed cluster sampling design), where S(a)/N(a)=
x(a) is the seronegative prevalence at age a. Force
of infection parameter estimates (and 95% CL) were
estimated by maximum-likelihood using previously
described methods [30, 35]. A best ﬁt model to the
data was derived with minimum number of force
of infection age classes using step-wise elimination
strategy. First we ﬁtted an 8 parameter model (i.e.
i=1, 8), with 5 year age classes from 0–4 years up to
25–29 years, and 10 year classes thereafter, estimating
the log-likelihood of the model. Age groups observed
to have similar li estimates were grouped and the
model reﬁtted. Comparison between the two models
was then achieved using the likelihood ratio test of the
two log-likelihoods (with degrees of freedom equal to
the diﬀerence in number of parameters between the
two models), and the constrained model accepted if
there was no signiﬁcant reduction in goodness of ﬁt.
The process was continued and a minimally speciﬁed
best-ﬁt model deﬁned as that with fewest parameters
(age classes) with a statistical ﬁt to the data no worse
than for the 8 parameter model.
Summary epidemiological parameters
Following themethods described elsewhere [30, 36, 37]
we calculated the average (arithmetic mean) age at
infection, A, the basic reproduction number, R0, and
the critical level of (successful) vaccination required
for elimination, pc (also known as the herd immunity
threshold, H), for hepatitis B in the population of
Addis Ababa.
We deﬁned incidence in age group a1 to a2 as
I=
Z a2
a1
l(a)X(a) da, (2)
where X(a) is the number of individuals of age a
susceptible to hepatitis B (i.e. without any HBV
marker), estimated from the predicted proportion
susceptible, xk(a) (see eqn (1)) divided by N(a), the
number of individuals of age a in urban Addis
Ababa, 1994 [31]. It follows that the average age
at infection, A is
A=
R1
0 al(a)X(a) daR1
0 l(a)X(a) da
: (3)
Solutions to eqns (2)–(3) were approximated using
discrete age intervals of 0.1 years, with an upper age
limit for eqn (3) of 99 years [30]. We adopted the
expression R0=1+B/A, where B is the reciprocal of
the crude birth rate (per 1000 head of population per
year), and pc=1x1/R0. Estimates of R0, and thus pc,
are crude approximations only, based upon the sim-
plifying assumptions of age-independence in the force
of infection, negligible inﬂuence of maternally derived
immunity in infancy, and simple demographic ap-
proximations [30]. A more detailed analysis is beyond
the scope of this paper.
RESULTS
A total of 8638 individuals from 1384 households
within 40 clusters (see Fig. 1) were registered in the
study, from whom 4777 blood samples were obtained.
Further details on the characteristics of the surveyed
population are found in other publications [29, 30].
Results are presented for 4736 individuals from 1262
households who were aged 0–49 years and had suf-
ﬁcient serum for serological analysis.
Serological results
Of the 4736 samples screened 292 (6.2%) were
HBsAg positive and 1734 (36.6%) were anti-HBc
positive. Within the group of HBsAg positive sam-
ples 13.7% (40) were anti-HBc negative, of which 24
were in children under 15 years old representing
38% of HBsAg positives in this age group. Of the
4444 HBsAg negative sera, 4414 had suﬃcient residue
for anti-HBs screening, of which 1796 (40.7%) had a
level of 10 mIU/ml or greater (seropositive). In the
data analysis, the 30 samples with insuﬃcient residue
were assigned the same status as for the correspond-
ing anti-HBc results (50% positive), since there was
good overall agreement (79%) between serological
status deﬁned by anti-HBc and anti-HBs. Suﬃcient
serum from 279 of the 292 HBsAg positive samples
was available for HBeAg screening, of which 71
(25.4%) were positive. Of samples with anti-HBs
levels o50 IU/l, 20% (236/1198) were anti-HBc
negative, whereas 65% (390/598) of the samples
with anti-HBs levels of 10–49 IU/l were anti-HBc
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negative. These 390 samples were considered equivo-
cal (i.e. probable false anti-HBs positives), and in
presenting the results the baseline assumption was to
assign these anti-HBs equivocal samples as negative,
with comparisons made using the alternative as-
sumption.
Prevalence of HBV markers
The prevalence of individuals with at least one
marker, standardized to the census population, was
44.8% (95% CI 42.7–47.1), and 55.7% (53.0–58.3) in
adults (15–49 years). These estimates become 53.1%
(50.5–55.8) and 63.5 (60.8–66.1), respectively, if we
assign as positive equivocal anti-HBs samples. Stan-
dardized HBsAg prevalence was 6.9% (5.9–8.0),
7.9% (6.8–9.3) for adults (15–49 years).
The prevalence distribution of markers for HBV
infection stratiﬁed by 5 year age classes is shown in
Figure 2. Estimates are weighted to account for
stratiﬁed cluster sampling. HBsAg prevalence showed
a rise from 3.1% (1.7–5.6) in 0–4 year olds to a peak
at 9.2% (6.1–13.8) in 30–34 year olds, and subsequent
decline to about 5% in 35–49 year olds. The pro-
portion of the population with at least one marker
of HBV infection was lowest in the 0–4 year olds
at 11.9% (8.5–16.3) and thereafter increased through-
out childhood and early adulthood to a plateau in the
40–49 year age group at around 74%. For individuals
with a marker of past infection but not current
(i.e. excluding HBsAg positives) most had both anti-
HBc and anti-HBs markers. The prevalence of
individuals with anti-HBs alone remained fairly con-
stant (average of 5%) throughout the age range,
whilst the proportion with anti-HBc alone increased
with age, particularly in the 40+ years age group,
such that in the age group 45–49 years the proportion
with anti-HBc alone exceeded that with both anti-
HBc and anti-HBs. Assigning equivocal anti-HBs
samples as positive led to an increase in overall
prevalence of markers, with higher impact in children
(standardized childhood seroprevalence is 24.0%
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Fig. 2. Age-prevalence of hepatitis B serological markers in Addis Ababa, 1994. The proportions positive for HBsAg, anti-
HBc alone, anti-HBc and anti-HBs, and anti-HBs alone, are deﬁned by bars of black, diagonal lines, grey, and open,
respectively. Prevalence estimates account for stratiﬁed cluster-based study design. Sample sizes for each 5 year age classes
were : 0–4, 422; 5–9, 622; 10–14, 796; 15–19, 902; 20–24, 606; 25–29, 397; 30–34, 283; 35–39, 329; 40–44, 191; 45–49, 188;
total, 4736.
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(21.2–27.1) for the baseline assumption and 33.2%
(29.6–37.1) assuming equivocal to be positive).
Comparison between males and females in the
proportion with the HBsAg marker (bars) or at least
one HBV marker (lines) is shown in Figure 3. The
prevalence over all ages (0–49 years) of HBsAg in
males was 8.6% (7.2–10.2), signiﬁcantly higher than
in females (4.6%; 3.6–5.7) (age-adjusted OR 2.08;
95% CI, 1.59–2.72). The male: female ratio in HBsAg
prevalence peaked at between 3:1 and 5:1 in the
25–29 to 35–39 year age classes. The prevalence of
individuals with at least one marker was higher for
males than females throughout the age range. The
overall prevalence of at least one marker for males
(44.1%; 39.3–43.7) was signiﬁcantly higher than for
females (41.4%, 42.3–47.0) (age-adjusted OR 1.43;
1.27–1.59).
Seroprevalence (standardized) of the HBeAg
marker in HBsAg positive individuals was 23.0%
(17.5–29.7), and highly age-dependent, as shown in
Figure 4, decreasing from 89.1% (53.1–98.3) in 0–4
year olds to 14.5% (9.5–21.4) in adults (15–49 years).
Controlling for age (child vs. adult) the prevalence
of HBeAg was signiﬁcantly higher in males (29.4%;
22.1–38.0) than females (19.7%; 13.9–27.2) (adjusted
OR 2.05; 1.08–3.15, interaction between age and sex
not signiﬁcant). In women of childbearing age (15–45
years) the prevalence of HBsAg positives was 4.9%
(3.8–6.4) in whom the proportion HBeAg positive
was 10.4% (456–18.7).
Comparison of marker prevalence in migrants and
non-migrants revealed no signiﬁcant diﬀerences. The
odds ratios (adjusted for age and sex) for HBsAg
and total prevalence in migrants relative to non-
migrant were 1.22 (0.89–1.66) and 1.15 (0.98–1.35),
respectively.
Incidence of HBV infection
Results of analysis using piece-wise catalytic infection
models are in Table 1. Data in single year age groups
(0–49 years) were prior weighted to account for
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Fig. 3. Age- and sex-stratiﬁed prevalence (and 95% CI) of HBsAg (bars) and any marker (lines) in Addis Ababa, 1994.
Female prevalence is indicated by open bars and by open markers (dashed line). Prevalence estimates and 95% CI account
for stratiﬁed cluster-based study design. Sample sizes for each 5 year age class, for males and females, are : 0–4, 225, 197; 5–9,
294, 328; 10–14, 358, 438; 15–19, 326, 576; 20–24, 233, 373; 25–29, 128, 269; 30–34, 108, 175; 35–39, 89, 240; 40–44, 60, 131;
45–49, 77, 111; total, 1898, 2838.
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stratiﬁed cluster-based design, and analysed in total
and by gender, and by assignment of equivocal anti-
HBs results as negative or positive. In each case re-
sults are presented for the best ﬁt age-dependentmodel
(2 parameters in each case) and the age-independent
(constant) model (1 parameter), showing the estimated
force of infection (with 95% CI) for each age class,
and likelihood estimate for the model ﬁt to the data
(xlog-likelihood). The likelihood ratio test (lr test)
comparisons all showed signiﬁcantly improved ﬁt to
the data for the 2 parameter models compared to the 1
parameter model, and a ﬁt to the 2 parameter model
that was no worse than that by the 8 parameter model.
Results shown in Table 1, under the assumption
that equivocal anti-HBs results are seronegative, in-
dicated an average force of infection (instantaneous
per susceptible incidence) for HBV of 3.1%/annum,
(i.e. 3.1/100 susceptibles/annum), slightly higher for
males and lower for females (constant model). How-
ever, age-dependence in transmission is supported
statistically indicating peak incidence rate in the total
population of 4.4%/annum in 0–4 year olds and
20–29 year olds, and a lower incidence of 2.2%/annum
in 5–19 year olds and 30–49 year olds (Table 1). The
same age-related pattern was detected for males, with
peak incidence of 5.5%/annum, but for females, a
higher incidence in the 0–4 year olds was not sup-
ported statistically, only in the 20–29 year age group
(4.1%/annum). Incidence estimates by gender are
graphically presented in Figure 5, together with the ﬁt
of the best model to single year age-prevalence data.
By comparison, analysis in which equivocal anti-
HBs were assigned as positive lead to an overall in-
crease in force of infection estimates (average for total
data 4.0%/annum; 3.9–4.2) with similar but more
exaggerated age-dependent patterns for the force of
infection, including a signiﬁcant second peak inci-
dence in females in age group 0–4 years.
Summary epidemiological parameters
Around 50% of individuals had at least one marker
by age 20–24 years (Fig. 2). Given the age structure of
the population and the age-related forces of infection
(Table 1), the modal ages for incidence, I, were 0–4
years and 20–24 years. The arithmetic mean age at
infection, A was 17.6 years (males 16.8 years ; females
18.7 years). Resultant estimates for R0 lay between 2.7
and 4.1 (dependent upon the assumed crude birth rate
of between 35.5 and 15.5/1000 per annum [30]), from
which the critical fraction to vaccinate eﬀectively for
elimination is estimated to lie in the range 63–75%.
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Fig. 4.HBeAg prevalence in HBsAg positives in Addis Ababa, 1994. Prevalence estimates account for stratiﬁed cluster-based
study design. Sample size for males (ﬁlled bars) and females (open bars), respectively, are indicated above each bar, with total
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Repeated analysis assigning as seropositive the
equivocal low anti-HBs samples lead to no substan-
tial change in these estimates; the predicted values for
A, A50, R0 and H become 16.2 and 20 years, 2.8–4.2,
and 64–76%, respectively.
DISCUSSION
Data are presented for an unusually large and detailed
serological survey of hepatitis B virus in an urban sub-
Saharan African population. The sample was broadly
representative of the population of Addis Ababa
judged by similarity with the 1994 census in age- and
sex-structure [29, 30] and in various social, econ-
omic and demographic characteristics (e.g. ethnicity,
educational status, migrancy, household size [38].
Estimates of marker prevalence took account of the
stratiﬁed cluster-based design. Where appropriate
prevalence estimates were standardized to the popu-
lation census to account for age and sex bias in blood
sample response rates (adult males being the least
willing [29, 30, 38]).
HBV prevalence (past or current infection) was
estimated to lie somewhere between 45% and 53%
(56–63% in adults aged 15–49 years), with HBsAg
prevalence (i.e. current infection) of 7% (in adults
8%). A steady rise in seroprevalence (any marker)
throughout childhood was observed, continuing in
adulthood, rising to 70–80% in those aged 45–49
years, indicative of signiﬁcant adult and childhood
Table 1. Force of infection estimates for HBV in Addis Ababa, 1994
Equivocal
assignment* Group
Model
(parameters)
Age classes
(years)
FOI
estimate (%) 95% CI x(log-likelihood) Lr test#
Negative Total Constant (1) 0–49 3.1$ 2.9–3.2 2905.06 2vs.1 15.60
P=0.0001
Best ﬁt (2) 0–4/20–29 4.4 4.1–4.7 2897.26 2vs.8 3.30
P=0.7704
5–19/30–49 2.2 2.0–2.4
Males Constant (1) 0–49 3.6 3.3–3.9 1158.16 2vs.1 12.72
P=0.0004
Best ﬁt (2) 0–4/20–29 5.5 4.9–6.1 1151.80 2vs.8 4.06
P=0.6686
5–19/30–49 2.3 1.9–2.7
Females Constant (1) 0–49 2.8 2.6–3.0 1727.35 2vs.1 5.01
P=0.0252
Best ﬁt (2) 0–19/30–49 2.6 2.4–2.8 1724.84 2vs.8 2.74
P=0.8399
20–29 4.1 3.2–5.0
Positive Total Constant (1) 0–49 4.0 3.9–4.2 3030.29 2vs.1 52.22
P<0.0001
Best ﬁt (2) 0–4/20–29 6.8 6.4–7.2 3004.17 2vs.8 10.81
P=0.0946
5–19/30–49 2.2 1.9–2.5
Males Constant (1) 0–49 4.6 4.3–4.9 1197.51 2vs.1 32.38
P<0.0001
Best ﬁt (2) 0–4/20–29 8.2 7.4–8.9 1181.32 2vs.8 3.82
P=0.7007
5–19/30–49 2.2 1.7–2.7
Females Constant (1) 0–49 3.7 3.5–3.9 1819.29 2vs.1 17.38
P<0.0001
Best ﬁt (2) 5–19/30–49 5.7 5.2–6.2 1810.60 2vs.8 7.09
P=0.3124
0–4/20–29 2.4 2.1–2.7
* Indicates whether equivocal anti-HBs samples were assigned as seronegative or seropositive (see text for details).
# Lr test, likelihood ratio test. 2vs.1 and 2vs.8 indicate comparisons between models of diﬀerent numbers of parameters.
xlog-likelihood for 8 parameter model (equivocals assigned negative) : total 2895.61; male 1149.77 ; female 1723.47.
(equivocals assigned positive) : total 2998.77 ; male 1179.41; female 1807.05.
$ 3.1%/annum is per susceptible incidence, i.e. 3.1/100 susceptibles/annum.
HBV seroepidemiology in Ethiopia 765
transmission. Although one quarter of individuals
currently infected (HBsAg positive) were positive for
a marker of active viral replication and high infec-
tiousness (HBeAg), only about 5 in 1000 women of
childbearing age were estimated to be highly infec-
tious, that is, of the 5% HBsAg positive, 11% were
HBeAg positive. This suggests the risk of perinatal
transmission to be low. Many of these features are
in common with surveys from other countries in East
Africa, such as Kenya [7, 39], and intermediate en-
demicity countries in Mediterranean North Africa,
such as Tunisia [40, 41]. Signiﬁcant childhood hori-
zontal transmission, and a HBsAg prevalence in ex-
cess of 5–8%, are features ascribed to high endemicity
[8, 42]. Nevertheless, within sub-Saharan African
countries adult surface antigen prevalence is fre-
quently well in excess of 10%, and the proportion of
adults with evidence of HBV infection in excess of
75% [8]. The contrast in HBV transmission rates is
particularly acute with West African countries (e.g.
The Gambia [11] and Senegal [1, 5]). A useful com-
parative measure of the magnitude of transmission is
the age at which 50% of the population have experi-
enced HBV infection, A50 [16]. In Addis Ababa the
value of A50 is around 20 years of age, compared with
less than 10 years in The Gambia and Senegal. These
comparisons suggest Addis Ababa to be of inter-
mediate–high HBV endemicity.
Previous serological data from Ethiopia are gen-
erally consistent with the ﬁndings reported here. A
countrywide study published in 1986 [9] recorded
HBV prevalence of 40% (76% in adults >15 years),
HBsAg prevalence of 6% (12% in adults), a preva-
lence of HBeAg in HBsAg positives of 26% (9% in
adults) and an A50 >15 years. Data for Addis Ababa
from the same study showed no diﬀerences from these
averages. A national survey of male military recruits
[20] gave an average prevalence of HBsAg of 10.8%
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Fig. 5. Age- and sex-related pattern of HBV incidence in Addis Ababa, 1994. (a) Shows for males the best ﬁt (2 parameter)
piece-wise constant (PWC) catalytic infection model (solid line) to yearly age–prevalence data (i.e. proportions with at least
one marker) (markers). (b) For females. (c) Records the estimated age-speciﬁc forces of infection (/susceptible/year), and
95% CI, from the best-ﬁt PWC (males, grey bars ; females, open bars). For comparison the age-independent force of
infection estimate is shown (males, solid line ; females, dotted line).
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and of any marker of 73.3%, and in male blood do-
nors in NW Ethiopia HBsAg prevalence was reported
as 14.4% [24]. A study of HBsAg carrier pregnant
women in Addis Ababa [28] provided direct evidence
of the low risk of perinatal transmission. Whilst esti-
mates of HBsAg prevalence of 10–14% and sero-
prevalence of 76–79% for Ethiopian adults [9, 20,
24, 27] appear higher than those observed in this
study, the low precision of prevalence estimates in
some of the earlier studies, and diﬀerences between
studies in age representations and sampling criteria,
make quantitative comparison diﬃcult. Regional dif-
ferences in HBV marker prevalence are observed
in Ethiopia [9, 20, 24], which might aﬀect prevalence
in Addis Ababa in view of the considerable in-
migration over the past 20 years. However, we could
ﬁnd no evidence of diﬀerent marker prevalence
between long-term residents and migrants (resident
<10 years).
We found evidence for the occurrence of false low
positive anti-HBs results. Primary analysis was based
on assigning as seronegative anti-HBc negative sam-
ples with low anti-HBs levels (10–49 mIU/ml), which
is the most likely explanation. Assigning equivocal
anti-HBs samples as positive, resulting in higher sero-
prevalence and increased age-related heterogeneity,
was viewed as the less likely alternative. The impli-
cations of these diﬀerences to the summary epidemi-
ological statistics, such as the herd immunity thresh-
old, are not substantial.
Higher prevalence of HBsAg in males compared
to females has been observed in numerous studies in
low, intermediate and high endemicity countries, and
is apparently ubiquitous. This may be attributable to
a higher probability following infection of becoming
a carrier in males than in females [43–45]. However,
other factors may be important, such as a sex diﬀer-
ential in the rate of infection (as observed in this
study) or in the duration of carriage, and further in-
vestigation would be of interest. The HBsAg male:
female prevalence ratio of roughly 2:1 (age adjusted
odds ratio of 2.1; 95% CI 1.6–2.7) in this study is
consistent with previous work in Ethiopia [9], and in
Kenya [7]. The pattern of rapid decline in HBeAg
prevalence in HBsAg positives has been observed in
both African [7] and East Asian [46] communities. It
is interesting to note the signiﬁcantly higher HBeAg
prevalence in male HBsAg positives than females in
a ratio of roughly 3:2 (age adjusted odds ratio of 2.1,
95% CI 1.1–3.2) and independent of age. Thus, not
only are males more likely to be currently infected but
also they are more infectious than females. A study in
Cameroon [43] observed higher prevalence of HBV-
DNA in males than in females in children, indicative
of higher infectivity of males perhaps due to slower
clearance of the virus.
Age-dependence in the force of infection has been
investigated using age-seroprevalence data based upon
the assumption of a steady state in HBV transmission
in the population. This assumption is reasonable
insofar as studies that precede the current survey are
similar in marker prevalence, and, although Addis
Ababa is undergoing a demographic transition, there
is no evidence to link changes in population density
with HBV transmission [16, 47].
A main ﬁnding from the present study was the
identiﬁcation of age- and gender-related patterns in
seroprevalence (anymarker) and consequently inHBV
incidence per susceptible (termed the force of infec-
tion). The average force of infection was calculated
to be 3–4% per year (i.e. 3–4/100 susceptibles per
annum). However, there was higher seroprevalence
(any marker) in males than females throughout the
age proﬁle (Fig. 3), leading to a marked gender dif-
ference in the age-acquisition of HBV (male 3.6%/
year; female 2.8%/year). This observation is unusual
in intermediate or high endemicity countries and only
previously reported in Kenya (in adults but not chil-
dren [7], and in a study of Ghanaian children [6]. The
diﬀerence in seroprevalence between males and fe-
males is established early in life (0–4 year age group)
with no obvious increase in divergence with age. This
suggests an early sex diﬀerential in the risk of acquir-
ing HBV, and the estimated HBV incidence for males
was over twice that for females at this age. Further
age-heterogeneity was identiﬁed in the age group
20–29 years in which both male and female seropreva-
lence rose more steeply than adjacent age groups,
resulting in signiﬁcantly higher incidence estimates.
Few studies have analysed incidence patterns for
HBV in developing countries. A review by Edmunds
et al. [16] of highly endemic areas (sub-Saharan Africa
and East Asia) revealed a general trend for higher in-
cidence (force of infection) in younger children than
older. Age-related patterns of HBV incidence may not
be readily discernable by eye from age-seroprevalence
data, and require statistical analysis of the form used
in this study to be resolved. This may be particularly
the case for adults where only a relatively small pro-
portion remain susceptible. Our work is the ﬁrst, of
which we are aware, to have analysed seroprevalence
data across both childhood and adult age ranges in
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a developing country and also to have identiﬁed age-
variation in adult incidence.
The patterns of incidence identiﬁed in this study
probably reﬂect underlying behavioural and social
heterogeneity between the sexes and between age
groups. Age-related diﬀerences in the force of infec-
tion might arise from variation in the contribution of
diﬀerent routes of transmission, for example, an in-
creased role for sexual transmission in young adults.
Higher incidence in young males (age 0–4 years) may
be indicative of risk-behaviour diﬀerences between
the sexes restricted to early years of life. Such obser-
vations suggest areas to target research. The mech-
anism by which horizontal transmission in childhood
is eﬀected remains a phenomenon. We might specu-
late on cultural practices such as male circumcision as
playing a role. Anthropological investigation of the
gender diﬀerences in behaviour of young children is
required to shed some light on the situation. Core
groups who, through behavioural characteristics, are
more likely to be infected and thus to infect others
are thought to be of considerable importance to the
persistence of HBV in low endemicity settings [13].
The results of this study show that also in the
medium–high endemicity setting adult sexual trans-
mission may be of importance, and further investi-
gation of HBV seroprevalence in relation to patterns
of sexual behaviour would be merited. It remains
the case that higher incidence in young adults may
arise through an increase in horizontal non-sexual
transmission. There is a general lack of understand-
ing of the routes of HBV transmission in adults in de-
veloping countries, highlighted by our observations.
Finally, disentangling the role of social-behavioural
characteristics from innate age or genetic factors, in
generating patterns of age-prevalence is complicated.
It is possible, for example, that the observed diﬀer-
ential in carrier prevalence (HBsAg) and infectivity
(HBeAg positive carriers), between the sexes (which
may have a genetic or behavioural origin), could
generate higher male seroprevalence, assuming, that
is, there was signiﬁcant within-gender contact rates.
The reverse might also be the case, i.e. higher inci-
dence of HBV in young males (where the risk of be-
coming a carrier is far higher than at older ages [48]),
due to some sex diﬀerence in behaviour, could play
a role in the higher male carrier prevalence.
The intrinsic capacity for spread of HBV in Addis
Ababa, as deﬁned by the basic reproductive rate, R0,
is estimated to be around 3–4. This represents a low
potential relative to typical childhood contagious
diseases such as measles and rubella [10, 30]. The dif-
ference in transmissibility of rubella and HBV, in the
same population at the same time, is reﬂected also in
the average age at infection (HBV>15 years ; rubella
5 years) and A50 (HBV y20 years ; rubella 4 years)
[30]. Our estimates of R0 are based on simplifying as-
sumptions about demography and mixing patterns,
and are therefore only approximate. Demographi-
cally, AddisAbaba is a population undergoingmarked
decline in fertility, leading to progressive reduction
in the proportional representation of children in the
population. The impact on HBV endemicity of such
demographic transition is thought to be complex-
unidentiﬁable in the short term but potentially cata-
strophic in the long term [49], – and further study
is warranted in this area given the general trend for
demographic transition in the developing world. Fur-
thermore, this recent theoretical work [49] suggests
that similar levels of marker prevalence may arise
from widely diﬀerent values of R0. However, the level
of HBV prevalence identiﬁed from our study would
remain consistent with values of R0 <3. In addition,
an analysis based on a fully age-structured math-
ematical model of HBV transmission in The Gambia
[15] gave an estimate of R0 y2 for this high endem-
icity country.
Thus calculations of the critical vaccination pro-
portion for elimination of HBV in Addis Ababa of
between 63–75% are unlikely to be underestimates.
Given that perinatal transmission in this population
is uncommon, it is likely that delivery of vaccine with
routine DPT where current uptake is over 70% for
three doses, would, in the long run be a successful
control policy. A recent survey in Addis Ababa
showed that of the increase in cost (40%) associated
with an introduction of HBV vaccine into the EPI
schedule, most of it (79%) would be the cost of vac-
cine (assumed to be US$0.5 per dose) [50]. If HBV
vaccine costs continue to decline with growth of the
world market, vaccine intervention will become in-
creasingly cost-eﬀective. However, Addis Ababa is
not representative of Ethiopia in general, not so much
in terms of the regional diﬀerences in HBV seropre-
valence in Ethiopia, which are not dramatic [9, 20, 24],
but in the level of routine vaccine coverage achieved,
the national average being 51% in 2000/2001 with
wide regional variation (personal communication,
EPI, Ministry of Health, Addis Ababa). This does not
necessarily argue against introducing HBV vaccine
into the national EPI schedule, since low level cover-
age is predicted to have signiﬁcant impact on carriage
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prevalence [11], but rather that a national elimination
policy would be unrealistic at present.
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